Preface...Table of Contents...Contributing Authors...1. RNA and CRISPR Interferences: Past, Present and Future Perspectives Mouldy Sioud2. Chemical Modifications in RNA Interference and CRISPR/Cas Genome Editing ReagentsKim A. Lennox and Mark A. Behlke3. Preparation, Determination of Activity, and Biodistribution of Cholesterol-Containing Nuclease-Resistant siRNAs In VivoIvan V. Chernikov, Mariya I. Meschaninova, and Elena L. Chernolovskaya4. Multifunctional Nanodelivery Platform for Maximizing Nucleic Acids Combination TherapySeung Koo Lee, Benedict Law, and Ching-Hsuan Tung5. PAMAM Dendrimers as a Delivery System for Small Interfering RNAShiva Kheiriabad, Maryam Ghaffari, Jafar Ezzati Nazhad Dolatabadi, and Michael R. Hamblin6. Delivery of Functional Small RNAs via Extracellular Vesicles In Vitro and In VivoDuo Zhang, Heedoo Lee, and Yang Jin7. Optimized siRNA Delivery into Primary Immune Cells using Electroporation Mouldy Sioud 8. Synthesis and Evaluation of Caged siRNAs with Single cRGD Modification for Photoregulating RNA InterferenceLijia Yu, Duanwei Liang, Nannan Jing, Changmai Chen, and Xinjing Tang9. Exploring 5'-Biotinylation of the Sense Strand to Improve siRNA Specificity and Potency Anne Mobergslien and Mouldy Sioud10. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs using an Ancestral Adeno-Associated Viral VectorNjabulo Mnyandu, Patrick Arbuthnot, and Mohube Betty Maepa11. Generating DNA Expression Cassettes Encoding Multimeric Artificial MicroRNA PrecursorsFiona T. van den Berg, Abdullah Ely, and Patrick Arbuthnot12. MiR-302-Mediated Somatic Cell Reprogramming and Method for Generating Tumor-Free iPS Cells Using miR-302Shi-Lung Lin, Jack S. Chen, and Shao-Yao Ying13. Urinary MicroRNAs as Emerging Class of Noninvasive BiomarkersJaroslav Juracek and Ondrej Slaby14. Improving Dendritic Cell Cancer Vaccine Potency using RNA Interference Stein Sæbøe-Larssen and Mouldy Sioud15. Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies using RNA Interference Mouldy Sioud16. Harnessing the Antiviral-Type Responses Induced by Immunostimulatory siRNAs for Cancer ImmunotherapyPer Ole Iversen and Mouldy Sioud17. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing Karin Zins and Dietmar Abraham18. Use of RNA Interference with TCR Transfer Enhance Safety and EfficiencyNicholas Paul Casey, Jon Amund Kyte, and Hiroshi Fujiwara19. CRISPR/Cas9 Guide RNA Design Rules for Predicting ActivityKasidet Hiranniramol, Yuhao Chen, and Xiaowei Wang20. CRISPR/Cas9 Genome Editing in Human Cell Lines with DONOR Vector Made by Gibson AssemblyNirakar Sahoo, Victoria Cuello, Shreya Udawant, Carl Litif, Julie A. Mustard, and Megan Keniry21. Genome Editing in Zebrafish using High-Fidelity Cas9 Nucleases: Choosing the Right Nuclease for the TaskSergey V. Prykhozhij, Anna Cordeiro-Santanach, Lucia Caceres, and Jason N. Berman22. Next Generation of Adoptive T Cell Therapy using CRISPR/Cas9 Technology: Universal or Boosted? Sébastien Walchli and Mouldy Sioud23. Engineering T-Cells using CRISPR/Cas9 for Cancer TherapyXingying Zhang, Chen Chen, Wen Sun, and Haoyi Wang24. CRISPR/Cas9 Mediated Genome Engineering of Primary Human B Cells Kanut Laoharawee, Matthew J. Johnson, and Branden S Moriarity 25. Gene Editing in B-Lymphoma Cell Lines using CRISPR/Cas9 TechnologyBaoyan Bai, June Helen Myklebust, and Sébastien Wälchli26. Gene Knockout in Hematopoietic Stem and Progenitor Cells followed by Granulocytic DifferentiationPerihan Mir, Malte Ritter, Karl Welte, Julia Skokowa, and Maksim Klimiankou27. CRISPR/Cas9 Genome Editing of Human Induced Pluripotent Stem Cells followed by Granulocytic DifferentiationBenjamin Dannenmann, Masoud Nasri, Karl Welte, and Julia Skokowa... Mehr
Preis-Alarm
